Pediatrics clinical trials

Explore recruiting pediatrics clinical trials.

Recruiting pediatrics studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pediatrics trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 1/2, OPEN-LABEL, EXPLORATORY CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DT-DEC01 THERAPY IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY

Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Tolerability and acceptance study of two oral hydrocortisone magistral formulations for pediatrics

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA

Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema [Donidalorsen Treatment in Children with Hereditary Angioedema]

Italy, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

(MOTOR Study) Neuromuscular MOniTOring in pediatric anesthesia. Randomized clinical study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/II, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX -101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or who have no Satisfactory Treatment Options

Germany, Italy, France, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pediatrics trials by city

Pediatrics in Toronto Pediatrics in Vancouver Pediatrics in Montreal Pediatrics in Calgary Pediatrics in Edmonton Pediatrics in Ottawa Pediatrics in Winnipeg Pediatrics in Quebec City Pediatrics in Hamilton Pediatrics in Kitchener Pediatrics in London Pediatrics in Halifax Pediatrics in New York Pediatrics in Los Angeles Pediatrics in Chicago Pediatrics in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease